

22. A peptide having the amino acid sequence:

Val-Ala-Leu-Asn-Ser-Pro-Leu-Ser-Gly-Gly-Met-Arg-Gly-Ile-Arg-Gly-Ala-Asp-Phe-Gln-
Cys-Phe-Gln-Gln-Ala-Arg-Ala-Val-Gly-Leu-Ala-Gly-Thr-Phe-Arg-Ala-Phe-Leu-Ser-Ser-Arg-Leu-
Gln-Asp-Leu-Tyr-Ser-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Ile-Val-Asn-Leu-Lys-Asp-
Glu-Leu-Leu-Phe-Pro-Ser-Trp-Glu-Ala-Leu-Phe-Ser-Gly-Ser-Glu-Gly-Pro-Leu-Lys-Pro-Gly-Ala-
Arg-Ile-Phe-Ser-Phe-Asp-Gly-Lys-Asp-Val-Leu-Arg-His-Pro-Thr-Trp-Pro-Gln-Lys-Ser-Val-Trp-
His-Gly-Ser-Asp-Pro-Asn-Gly-Arg-Arg-Leu-Thr-Glu-Ser-Tyr-Cys-Glu-Thr-Trp-Arg-Thr-Glu-Ala-
Pro-Ser-Ala-Thr-Gly-Gln-Ala-Ser-Ser-Leu-Leu-Gly-Gly-Arg-Leu-Leu-Gly-Gln-Ser-Ala-Ala-Ser-
Cys-His-His-Ala-Tyr-Ile-Val-Leu-Cys-Ile-Glu-Asn-Ser-Phe-Met-Thr-Ala-Ser (HF-COLL-18/514cf)

(SEQ ID NO: 1).

23. Amidated, acetylated, phosphorylated and glycosylated derivatives of the peptide of claim 22.
24. A process for the preparation of the peptide according to claim 22 and/or its pharmacologically active fragments through prokaryotic or eukaryotic expression.
25. A process for the preparation of the peptide according to claim 22 and/or its pharmacologically active fragments through isolation from human blood using chromatographic methods.
26. A process for the preparation of the peptide or its derivatives according to claim 22 and/or its pharmacologically active fragments by solid-phase and liquid-phase synthesis and

purification by chromatographical methods.

- B2
27. Medicaments containing the peptide according to claim 22 or its pharmacologically active fragments as the active ingredient in combination with excipients.
 28. Medicaments according to claim 22 for oral, parenteral, intravenous, intramuscular, intracutaneous, intrathecal, intranasal or local-topical application or in the form of an aerosol for transpulmonary application.
 29. Antibodies obtainable by immunizing animals with the peptide according to claim 22 and/or its pharmacologically active fragments, and/or and/or its amidated, acetylated, phosphorylated, and glycosylated derivatives, by using hybridoma technology.
 30. A method for the treatment of patients in need of an inhibition of HF-COLL-18/514cf or its derivatives or fragments according to claim 22 by the administration of therapeutic amounts of an antagonist/inhibitor of HF-COLL-18/514cf.
 31. A method for the treatment of patients in need of an inhibition of HF-COLL-18/514cf or its derivatives according to claim 22 or its pharmacologically active fragments by the administration of therapeutic amounts of antagonist/inhibitor of HF-COLL-18/514cf.
 32. Method of using the medicaments according to claim 27 by administration to a human patient for the treatment of diseases in connection with capillary proliferations.
 33. Method of using the medicaments according to claim 27 by administration to a human patient for the treatment of carcinoses.
 34. Method of using the medicaments according to claim 27 by administration to a human

patient for the treatment of diseases involving the cardiovascular and nervous systems.

35. Method of using the medicaments according to claim 27 by administration to a human patient for the treatment of diseases involving the integument and the sense organs.

36. Method of using the peptide or its derivatives according to claim 22, its pharmacologically active fragments, or an antibody obtainable by immunizing an animal with said peptide and/or its pharmacologically active fragments and/or by using hybridoma technology by formulation as a medicament for the treatment of disorders in inflammatory processes, disturbed inflammatory reactions, proliferation and maturation disorders of the blood-forming system.

37. Method of using the medicaments according to claim 27 or an antibody obtainable by immunizing an animal with said peptide and/or its pharmacologically active fragments and/or by using hybridoma technology by administration to a human patient for the treatment of systemic diseases resulting from overproduction or deficiency of HF-COLL-18/514cf.

38. Method of using the medicaments according to claim 27 by administration to a human patient for the treatment of tumor and vascular diseases.

39. Method of using the medicaments according to claim 27 or an antibody obtainable by immunizing an animal with said peptide and/or its pharmacologically active fragments and/or by using hybridoma technology by administration to a human patient for the treatment of acute diseases in intensive care.

40. Method of using the medicaments according to claim 27 or an antibody obtainable by